GlassScriptPhysician profile
Chastity Heath
NPI 1003205857
$5,497.45
in general payments reported to CMS, 2019-2025
32 companies · $2,275 in 2025
The $2,275 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $94.24 · 2024: $2,996 · 2025: $2,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082 · Travel and Lodging: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,081.74 |
| Travel and Lodging | $1,189.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,432.64 | 2024-2025 | Watchman Flx, Ingevity+ |
| Pfizer INC. | $465.46 | 2024-2025 | |
| Amgen INC. | $347.73 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $334.33 | 2025 | |
| Philips North America LLC | $251.49 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, Mcot |
| Merck Sharp & Dohme LLC | $223.75 | 2024-2025 | Verquvo |
| Abiomed | $221.50 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $221.34 | 2024-2025 | |
| Medtronic, INC. | $196.54 | 2024-2025 | Cobalt Dr Mri Surescan, Corevalve Evolut R, Linq II |
| E.R. Squibb & Sons, L.L.C. | $191.51 | 2024-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $181.40 | 2024-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $167.36 | 2024 | Xarelto |
| Novo Nordisk INC | $148.60 | 2024-2025 | Wegovy, Ozempic |
| Alnylam Pharmaceuticals INC. | $135.01 | 2025 | Amvuttra |
| Abbott Laboratories | $122.53 | 2025 | Jot Dx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.92 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.05 | 2024-2025 | Jardiance |
| Edwards Lifesciences Corporation | $113.73 | 2024 | Sapien 3 Ultra Resilia |
| Genentech USA, INC. | $109.02 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.52 | 2025 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $59.23 | 2022 | |
| Bridgebio Pharma, INC. | $51.43 | 2025 | Attruby |
| Scpharmaceuticals INC. | $32.72 | 2024 | |
| Terumo Medical Corporation | $29.26 | 2024 | Glidewire |
| Abbvie INC. | $26.55 | 2021 | |
| Ionis Pharmaceuticals, INC. | $26.45 | 2025 | |
| Biotronik INC. | $22.04 | 2025 | Acticor 7 Vr-T Dx |
| Irhythm Technologies, INC. | $20.96 | 2024 | Zio Monitor, Zio Xt Patch |
| Glaxosmithkline, LLC. | $17.44 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.29 | 2021 | |
| Esperion Therapeutics, INC. | $14.12 | 2024 | Nexletol |
| Heartflow, INC. | $13.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chastity Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.